Tenderwize
Zurück zur Suche

Open-house rebate agreements for Lopinavir/Ritonavir

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Nov 30, 2027 · 462 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Lopinavir und Ritonavir, ATC J05AR10

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

58 / 100

Risikofaktoren

For the first contract start, documents must be received by 31.12.2025; the notice says receipt by the buyer is decisiv...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing Lopinavir and Ritonavir (ATC J05AR10).
  • Supply/contracting scope is limited to medicines that are authorised and marketable in Germany.
Vollständige Zusammenfassung anzeigen

This is a non-exclusive open-house supply arrangement for pharmaceutical products containing Lopinavir and Ritonavir (ATC J05AR10) offered by AOK Rheinland-Pfalz/Saarland. The contract period runs from 01.02.2026 to 31.01.2028, with monthly entry possible during the 24-month window. The notice explicitly excludes medicines listed as children’s medicines under the BfArM list (§ 35(5a) SGB V). No contract value is stated. Submission is not electronic-only: paper originals or electronically signed documents by email are allowed, and the notice says the first award/contract conclusion can occur no earlier than 10 days after publication.

Risiken

For the first contract start, documents must be received by 31.12.2025; the notice says receipt by the buyer is decisiv...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Medicines must be authorised and marketable in Germany.

Eligibility

  • Only pharmaceutical companies are eligible to become contract partners.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce public extract must be provided with specified product and authorisation details.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate agreements for Lopinavir/Ritonavir

Single open-house lot for non-exclusive rebate agreements covering medicines with the active substance Lopinavir and Ritonavir (ATC J05AR10). The buyer states that all interested pharmaceutical companies may join on equal terms, without individual negotiation or selection. Children’s medicines listed in the BfArM list are excluded. Contract duration is up to 24 months, starting no earlier than 01.02.2026, with monthly entry possible. The lot information comes from structured data and notice text.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Jan 2026 - Jan 2028

Kategorie

Pharmaceutical products

Frist

Deadline Nov 30, 2027

Vergabedetails

Veröffentlichungsdatum
09 Dec 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
819132-2025

Dokumente (1)

Ähnliche Ausschreibungen